Enterprise Decision Intelligence
Better Decisions.
Measurable Impact.
MDS Intel helps pharmaceutical commercial teams make better pricing, market access, launch, forecasting, portfolio, and commercial investment decisions through explainable analytics and decision science.
20+
Years of Experience
Pharma
Commercial Focus
Explainable
Decision Intelligence
About MDS Intel
Commercial judgment, strengthened by decision science.
MDS Intel is a pharmaceutical commercial decision-intelligence company focused on turning complex market signals, assumptions, and trade-offs into explainable decisions.
Built on 20+ years of experience across pricing, market access, launch, forecasting, real-world evidence, omnichannel strategy, and commercial analytics, the company is developing practical products for decisions where clarity and prioritization matter.
Decision Areas
Decisions We Improve
Decision science applied to the commercial questions that shape pharmaceutical performance.
Market Access
Product Launch
Forecasting and Assumptions
Commercial Investment
Portfolio Prioritization
Products in Development
Focused tools for consequential commercial decisions.
Two decision-intelligence products are currently being developed for distinct pharmaceutical commercial challenges.
AccessIQ
Explainable payer and account access-barrier prioritization for U.S. specialty pharma.
AccessIQ is in active development and is not presented as production-ready or customer-deployed.
PriceIQ Generics
Risk-adjusted molecule selection, NPV analysis, and launch prioritization for generic manufacturers.
The analytical prototype is being developed. The customer-facing interface and upload workflow are still in development.
Track Record
Experience measured in outcomes.
Selected commercial outcomes from prior work across pricing, specialty pharmacy, and patient analytics.
Margin protection
Protected margin through international reference pricing corridor re-sequencing for a European biosimilar launch.
Specialty-pharmacy revenue growth
Scaled a specialty-pharmacy commercial network from under $1M to $14M in revenue.
Adherence improvement
Improved adherence through machine-learning segmentation of financial and clinical dropout.
Insights
The Signal
Pharmaceutical commercial intelligence and commentary on pricing, market access, launch, analytics, and decision science.
Contact
Discuss a commercial decision that matters.
Connect with MDS Intel to discuss pharmaceutical commercial decision intelligence, products in development, or a consequential commercial decision.
siva@mdsintel.com